Get startedLog in
    Picture of Actuate Therapeutics logo

    ACTU — Actuate Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Brief: Actuate Announces FDA Rare Pediatric Disease Designation Granted To Elraglusib For Treatment Of Ewing Sarcoma

    Picture of Actuate Therapeutics logoActuate Therapeutics
    12/11/2024 13:20
    Nov 12 (Reuters) - Actuate Therapeutics Inc  ACTU.O :
    * ACTUATE ANNOUNCES FDA RARE PEDIATRIC DISEASE DESIGNATION
GRANTED
TO ELRAGLUSIB FOR TREATMENT OF EWING SARCOMA
    * ACTUATE THERAPEUTICS INC - TOPLINE PHASE 1 DATA FOR
ELRAGLUSIB
EXPECTED IN 2H 2025

Source text:  ID:nGNXc0gGtT 
Further company coverage:  ACTU.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Actuate Therapeutics

    See all news